Pin1 is required for ultraviolet A-stimulated cyclooxygenase-2 induction in mouse epidermal cells

Cancer Letters

Volumn 335, Issue 1, 2013, Pages 31-40

  Quyen, Bui Thu ^a   Choi, Hoo Kyun ^b   Kang, Keon Wook ^a  

^a Seoul National University   (South Korea)

^b Chosun University   (South Korea)

Author keywords

COX 2; Pin1; Transformation; UVA

Indexed keywords

AP 1 PROTEIN; CCAAT ENHANCER BINDING PROTEIN ALPHA; CCAAT ENHANCER BINDING PROTEIN BETA; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; CYCLOOXYGENASE 2; EPIDERMAL GROWTH FACTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PEPTIDYLPROLYL ISOMERASE PIN1; PROSTAGLANDIN E2; REGULATOR PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; COX 2 GENE; ENZYME INHIBITION; EPIDERMIS CELL; GENE ACTIVATION; GENE OVEREXPRESSION; GENETIC TRANSCRIPTION; MALIGNANT TRANSFORMATION; MOUSE; NONHUMAN; PIN GENE; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; PROTEIN EXPRESSION; RADIATION EXPOSURE; TRANSCRIPTION INITIATION; ULTRAVIOLET A RADIATION;

ANIMALS; CCAAT-ENHANCER-BINDING PROTEINS; CELL LINE; CELL TRANSFORMATION, NEOPLASTIC; CYCLIC AMP RESPONSE ELEMENT-BINDING PROTEIN; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; DINOPROSTONE; ENZYME ACTIVATION; ENZYME INDUCTION; EPIDERMAL GROWTH FACTOR; EPIDERMIS; EPITHELIAL CELLS; MICE; NAPHTHOQUINONES; NF-KAPPA B; PEPTIDYLPROLYL ISOMERASE; SIGNAL TRANSDUCTION; THIAZINES; THIAZOLES; TRANSCRIPTION FACTOR AP-1; ULTRAVIOLET RAYS;

EID: 84878425446     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2013.01.047     Document Type: Article

References (40)

1. Marks R. An overview of skin cancer. Incidence Causation. Cancer 1995, 75:607-612.
2. de Gruijl F.R. Photocarcinogenesis: UVA vs UVB. Methods Enzymol. 2000, 319:359-366.
3. Matsui M.S., DeLeo V.A. Longwave ultraviolet radiation and promotion of skin cancer. Cancer Cells 1991, 3:8-12.
4. Bachelor M.A., Bowden G.T. UVA-mediated activation of signaling pathways involved in skin tumor promotion and progression. Semin. Cancer Biol. 2004, 14:131-138.
5. Bakhle Y.S. COX-2 and cancer: a new approach to an old problem. Br. J. Pharmacol. 2001, 134:1137-1150.
6. Soslow R.A., Dannenberg A.J., Rush D., Woerner B.M., Khan K.N., Masferrer J., Koki A.T. COX-2 is expressed in human pulmonary, colonic and mammary tumors. Cancer 2000, 89:2637-2645.
7. Sawaoka H., Kawano S., Tsuji S., Tsujii M., Gunawan E.S., Takei Y., Nagano K., Hori M. Cyclooxygenase-2 inhibitors suppress the growth of gastric cancer xenografts via induction of apoptosis in nude mice. Am. J. Physiol. 1998, 274:1061-1067.
8. Blumenthal R.D., Waskewich C., Goldenberg D.M., Lew W., Flefleh C., Burton J. Chronotherapy and chronotoxicity of the cyclooxygenase-2 inhibitor, celecoxib, in athymic mice bearing human breast cancer xenografts. Clin. Cancer Res. 2001, 7:3178-3185.
9. Tang J.Y., Aszterbaum M., Athar M., Barsanti F., Cappola C., Estevez N., Hebert J., Hwang J., Khaimskiy Y., Kim A., Lu Y., So P.L., Tang X., Kohn M.A., McCulloch C.E., Kopelovich L., Bickers D.R., Epstein E.H. Basal cell carcinoma chemoprevention with nonsteroidal anti-inflammatory drugs in genetically predisposed PTCH1+/- humans and mice. Cancer Prev. Res. 2010, 3:25-34.
10. Orengo I.F., Gerguis J., Phillips R., Guevara A., Lewis A.T., Black H.S. Celecoxib, a cyclooxygenase 2 inhibitor as a potential chemopreventive to UV-induced skin cancer: a study in the hairless mouse model. Arch. Dermatol. 2002, 138:751-755.
11. Bayer E., Goettsch S., Mueller J.W., Griewel B., Guiberman E., Mayr L.M., Bayer P. Structural analysis of the mitotic regulator hPin1 in solution: insights into domain architecture and substrate binding. J. Biol. Chem. 2003, 278:26183-26193.
12. Weiwad M., Kullertz G., Schutkowski M., Fischer G. Evidence that the substrate backbone conformation is critical to phosphorylation by p42 MAP kinase. FEBS Lett. 2000, 478:39-42.
13. Bao L., Sauter G., Sowadski J., Lu K.P., Wang D. Prevalent overexpression of prolyl isomerase Pin1 in human cancers. Am. J. Pathol. 2004, 164:1727-1737.
14. Han C.Y., Hien T.T., Lim S.C., Kang K.W. Role of Pin1 in UVA-induced cell proliferation and malignant transformation in epidermal cells. Biochem. Biophys. Res. Commun. 2011, 410:68-74.
15. Fosslien E. Biochemistry of cyclooxygenase (COX)-2 inhibitors and molecular pathology of COX-2 in neoplasia. Crit. Rev. Clin. Lab. Sci. 2000, 37:431-502.
16. Masferrer J.L., Leahy K.M., Koki A.T., Zweifel B.S., Settle S.L., Woerner B.M., Edwards D.A., Flickinger A.G., Moore R.J., Seibert K. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res. 2000, 60:1306-1311.
17. Kim Y., Fischer S.M. Transcriptional regulation of cyclooxygenase-2 in mouse skin carcinoma cells. Regulatory role of CCAAT/enhancer-binding proteins in the differential expression of cyclooxygenase-2 in normal and neoplastic tissues. J. Biol. Chem. 1998, 273:27686-27694.
18. Hong J.T., Kim E.J., Ahn K.S., Jung K.M., Yun Y.P., Park Y.K., Lee S.H. Inhibitory effect of glycolic acid on ultraviolet-induced skin tumorigenesis in SKH-1 hairless mice and its mechanism of action. Mol. Carcinog. 2001, 31:152-160.
19. Tang Q., Chen W., Gonzales M.S., Finch J., Inoue H., Bowden G.T. Role of cyclic AMP responsive element in the UVB induction of cyclooxygenase-2 transcription in human keratinocytes. Oncogene 2001, 20:5164-5172.
20. Bell S., Degitz K., Quirling M., Jilg N., Page S., Brand K. Involvement of NF-kappaB signalling in skin physiology and disease. Cell Signal. 2003, 15:1-7.
21. Hsu T.C., Nair R., Tulsian P P., Camalier C.E., Hegamyer G.A., Young M.R., Colburn N.H. Transformation nonresponsive cells owe their resistance to lack of p65/nuclear factor-kappaB activation. Cancer Res. 2001, 61:4160-4168.
22. Xie Q.W., Kashiwabara Y., Nathan C. Role of transcription factor NF-κB/Rel in induction of nitric oxide synthase. J. Biol. Chem. 1994, 269:4705-4708.
23. Pentland A.P., Mahoney M., Jacobs S.C., Holtzman M.J. Enhanced prostaglandin synthesis after ultraviolet injury is mediated by endogenous histamine stimulation. J. Clin. Invest. 1990, 86:566-574.
24. Muller-Decker K., Scholz K., Marks F., Furstenberger G. Differential expression of prostaglandin H synthase isozymes during multistage carcinogenesis in mouse epidermis. Mol. Carcinogenesis 1995, 12:31-41.
25. Noble S., Balfour J.A. Meloxicam. Drugs 1996, 51:424-432.
26. Xie W., Chipman J.G., Robertson D.L., Erikson R.L., Simmons D.L. Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc. Natl. Acad. Sci. USA 1991, 88:2692-2696.
27. Xie W., Robertson D.L., Erikson R.L., Simmons D.L. Mitogen-inducible prostaglandin G/H synthase: a new target for nonsteroidal anti-infammatory drugs. Drug. Devel. Res. 1992, 25:249-265.
28. Bruls W.A., Slaper H., van der Leun J.C., Berrens L. Transmission of human epidermis and stratum corneum as a function of thickness in the ultraviolet and visible wavelengths. Photochem. Photobiol. 1984, 40:485-494.
29. Tripp C.S., Blomme E.A., Chinn K.S., Hardy M.M., LaCelle P., Pentland A.P. Epidermal COX-2 induction following ultraviolet irradiation: suggested mechanism for the role of COX-2 inhibition in photoprotection. J. Invest. Dermatol. 2003, 121:853-861.
30. Pentland A.P., Schoggins J.W., Scott G.A., Khan K.N., Han R. Reduction of UV-induced skin tumors in hairless mice by selective COX-2 inhibition. Carcinogenesis 1999, 20:1939-1944.
31. Pentland A.P., Jacobs S.C. Bradykinin-induced prostaglandin synthesis is enhanced in keratinocytes and fibroblasts by UV injury. Am. J. Physiol. 1991, 261:543-547.
32. Thompson E.J., Gupta A., Vielhauer G.A., Regan J.W., Bowden G.T. The growth of malignant keratinocytes depends on signaling through the PGE(2) receptor EP1. Neoplasia 2001, 3:402-410.
33. Tsujii M., Kawano S., Tsuji S., Sawaoka H., Hori M., Dubois R.N. Cyclooxygenase regualtaes angiogenesis induced by colon cancer cells. Cell. 1998, 93:705-716.
34. Tucker O.N., Dannenberg A.J., Yang E.K., Zhang F., Teng L., Daly J.M., Soslow R.A., Masferrer J.L., Woerner B.M., Koki A.T., Fahey T.J. Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer. Cancer Res. 1999, 59:987-990.
35. Fischer S.M., Lo H., Gordon G.B., Seibert K., Kelloff G., Lubet R.A., Conti C.J. Chemoprotective activity of celecoxib, a specific cyclooxegenase-2 inhibitor, and indomethacin against ultraviolet light-induced skin carcinogenesis. Mol. Carcinogenesis 1999, 25:231-240.
36. Jeong H.G., Pokharel Y.R., Lim S.C., Hwang Y.P., Han E.H., Yoon J.H., Ahn S.G., Lee K.Y., Kang K.W. Novel role of Pin1 induction in type II collagen-mediated rheumatoid arthritis. J. Immunol. 2009, 183:6689-6697.
37. Tak P.P., Firestein G.S. NF-kappaB: a key role in inflammatory diseases. J. Clin. Invest. 2001, 107:7-11.
38. Wardlaw S.A., Zhang N., Belinsky S.A. Transcriptional regulation of basal cyclooxygenase-2 expression in murine lung tumor-derived cell lines by CCAAT/enhancer-binding protein and activating transcription factor/cAMP response element-binding protein. Mol. Pharmacol. 2002, 62:326-333.
39. Ryo A., Suizu F., Yoshida Y., Perrem K., Liou Y.C., Wulf G., Rottapel R., Yamaoka S., Lu K.P. Regulation of NF-kappaB signaling by Pin1-dependent prolyl isomerization and ubiquitin-mediated proteolysis of p65/RelA. Mol. Cell 2003, 12:1413-1426.
40. Wulf G.M., Ryo A., Wulf G.G., Lee S.W., Niu T., Petkova V., Lu K.P. Pin1 is overexpressed in breast cancer and cooperates with Ras signaling in increasing the transcriptional activity of c-Jun towards cyclin D1. EMBO J. 2001, 20:3459-3472.